NovaBay Pharmaceuticals, Inc.
NBY
$0.60
$0.000.00%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.12M | 9.75M | 9.56M | 9.61M | 10.75M |
| Total Other Revenue | 27.00K | 34.00K | 9.00K | 2.00K | 0.00 |
| Total Revenue | 7.15M | 9.78M | 9.57M | 9.61M | 10.75M |
| Cost of Revenue | 2.46M | 2.46M | 2.67M | 2.65M | 3.63M |
| Gross Profit | 4.69M | 4.69M | 4.27M | 4.34M | 4.48M |
| SG&A Expenses | 10.77M | 10.36M | 9.67M | 9.38M | 9.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.25M | 12.84M | 12.36M | 12.03M | 13.16M |
| Operating Income | -6.10M | -5.69M | -5.41M | -5.05M | -5.05M |
| Income Before Tax | -7.45M | -7.05M | -7.44M | -7.58M | -7.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.45 | -7.05 | -7.44 | -7.58 | -7.73 |
| Earnings from Discontinued Operations | 11.11M | -178.00K | -2.68M | -3.08M | -3.39M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.66M | -7.22M | -10.12M | -10.66M | -11.12M |
| EBIT | -6.10M | -5.69M | -5.41M | -5.05M | -5.05M |
| EBITDA | -6.07M | -5.65M | -5.37M | -5.00M | -5.00M |
| EPS Basic | -0.68 | -32.07 | -78.45 | -90.96 | -133.90 |
| Normalized Basic EPS | -1.44 | -16.69 | -22.04 | -28.15 | -39.48 |
| EPS Diluted | -0.68 | -32.07 | -78.45 | -90.96 | -133.90 |
| Normalized Diluted EPS | -1.43 | -16.69 | -22.04 | -28.15 | -39.48 |
| Average Basic Shares Outstanding | 18.17M | 12.98M | 5.18M | 1.61M | 542.10K |
| Average Diluted Shares Outstanding | 18.28M | 12.98M | 5.18M | 1.61M | 542.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |